Information Provided By: 
Fly News Breaks for March 26, 2018
CTIC
Mar 26, 2018 | 07:42 EDT
Needham analyst Chad Messer initated CTI BioPharma with a Buy rating and a price target of $10, citing his view of pacritinib as an unusually de-risked asset based on the data from two Phase III studies and a "clear path to approval with the FDA". Messer adds that despite some recent recovery in the stock price, there is still "deep value" in CTI BioPharma shares. The analyst further notes the company's commercial presence with Pixuvri as a treatment in aggressive B-cell NHL which has a conditional approval in Europe.
News For CTIC From the Last 2 Days
There are no results for your query CTIC
